Free Trial

Allergy Therapeutics (AGY) Competitors

Allergy Therapeutics logo
GBX 7.08 -0.08 (-1.05%)
As of 06:18 AM Eastern

AGY vs. INDV, AMYT, APH, ANCR, VLG, DNL, EAH, STX, PXS, and CHLL

Should you be buying Allergy Therapeutics stock or one of its competitors? The main competitors of Allergy Therapeutics include Indivior (INDV), Amryt Pharma (AMYT), Alliance Pharma (APH), Animalcare Group (ANCR), Venture Life Group (VLG), Diurnal Group (DNL), ECO Animal Health Group (EAH), Shield Therapeutics (STX), Provexis (PXS), and Chill Brands Group (CHLL). These companies are all part of the "drug manufacturers - specialty & generic" industry.

Allergy Therapeutics vs.

Indivior (LON:INDV) and Allergy Therapeutics (LON:AGY) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their analyst recommendations, media sentiment, community ranking, institutional ownership, valuation, earnings, risk, profitability and dividends.

In the previous week, Indivior's average media sentiment score of 0.00 equaled Allergy Therapeutics'average media sentiment score.

Company Overall Sentiment
Indivior Neutral
Allergy Therapeutics Neutral

86.0% of Indivior shares are owned by institutional investors. 3.4% of Indivior shares are owned by company insiders. Comparatively, 93.0% of Allergy Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Indivior has a beta of 0.19, indicating that its share price is 81% less volatile than the S&P 500. Comparatively, Allergy Therapeutics has a beta of 1.4, indicating that its share price is 40% more volatile than the S&P 500.

Indivior has a net margin of -0.17% compared to Allergy Therapeutics' net margin of -72.86%. Indivior's return on equity of -0.77% beat Allergy Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Indivior-0.17% -0.77% 2.37%
Allergy Therapeutics -72.86%-266.59%-34.76%

Indivior has higher revenue and earnings than Allergy Therapeutics. Indivior is trading at a lower price-to-earnings ratio than Allergy Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Indivior£1.40B0.94-£2.36M-£1.21-695.65
Allergy Therapeutics£72.18M4.82-£52.59M-£1.04-6.82

Indivior currently has a consensus price target of GBX 1,650, suggesting a potential upside of 96.66%. Given Indivior's stronger consensus rating and higher probable upside, equities research analysts plainly believe Indivior is more favorable than Allergy Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Indivior
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
3.00
Allergy Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Indivior received 198 more outperform votes than Allergy Therapeutics when rated by MarketBeat users. Likewise, 80.43% of users gave Indivior an outperform vote while only 77.97% of users gave Allergy Therapeutics an outperform vote.

CompanyUnderperformOutperform
IndiviorOutperform Votes
559
80.43%
Underperform Votes
136
19.57%
Allergy TherapeuticsOutperform Votes
361
77.97%
Underperform Votes
102
22.03%

Summary

Indivior beats Allergy Therapeutics on 11 of the 16 factors compared between the two stocks.

Get Allergy Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for AGY and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

AGY vs. The Competition

MetricAllergy TherapeuticsDrug Manufacturers IndustryMedical SectorLON Exchange
Market Cap£347.74M£2.14B£5.33B£2.63B
Dividend Yield8.33%2.92%5.21%5.05%
P/E Ratio-6.823.9426.77134.99
Price / Sales4.82523.44393.27224,419.26
Price / Cash3.6610.2538.2528.03
Price / Book71.696.906.773.80
Net Income-£52.59M£20.70B£3.23B£5.88B
7 Day Performance-5.67%-0.98%0.43%0.38%
1 Month Performance9.69%3.23%9.07%21.44%
1 Year Performance108.09%94.36%18.57%129.76%

Allergy Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
AGY
Allergy Therapeutics
N/AGBX 7.08
-1.0%
N/A+116.7%£347.74M£72.18M-6.82612High Trading Volume
INDV
Indivior
N/AGBX 841
-0.6%
GBX 1,650
+96.2%
-37.0%£1.31B£1.40B-697.311,000News Coverage
AMYT
Amryt Pharma
N/AN/AN/AN/A£457.11M£210.24M-4.33290Gap Down
APH
Alliance Pharma
1.853 of 5 stars
GBX 64.70
flat
GBX 6,250
+9,560.0%
N/A£350.32M£183.50M-10.4391,000High Trading Volume
ANCR
Animalcare Group
N/AGBX 248.80
+1.1%
N/A+5.5%£170.58M£84.90M4.64220High Trading Volume
VLG
Venture Life Group
N/AGBX 50
+5.0%
N/A+25.6%£63.71M£51.77M84.85165News Coverage
Gap Up
DNL
Diurnal Group
N/AN/AN/AN/A£46.33M£4.68M-3.2133
EAH
ECO Animal Health Group
N/AGBX 62.90
+0.6%
N/A-47.6%£42.62M£89.44M40.66234Gap Up
High Trading Volume
STX
Shield Therapeutics
N/AGBX 2.35
-6.0%
N/A+19.1%£23.19M£20.92M-0.6140,000
PXS
Provexis
N/AGBX 0.52
-1.0%
N/A-10.7%£12.20M£846,984.38-19.714Gap Up
CHLL
Chill Brands Group
N/AN/AN/AN/A£10.89M£624,187.00-215.007

Related Companies and Tools


This page (LON:AGY) was last updated on 5/23/2025 by MarketBeat.com Staff
From Our Partners